ClinVar Miner

Submissions for variant NM_000404.4(GLB1):c.464T>G (p.Leu155Arg) (rs376710410)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000256106 SCV000321730 pathogenic not provided 2016-04-19 criteria provided, single submitter clinical testing The L155R pathogenic variant in the GLB1 gene has been reported previously in the homozygous state in an individual with type III (adult) GM1-gangliosidosis (Santamaria et al., 2007). This variant was also reported in three other individuals with adult or late infantile GM1-gangliosidosis, each of whom also harbored a second GLB1 pathogenic variant, although the phase of the variants could not be confirmed, as parental testing was not performed (Hofer et al., 2009; Hofer et al., 2010). Functional studies demonstrate that the L155R variant reduces beta-galactosidase activity (Hofer et al., 2009). This variant was not observed at any significant frequency in approximately 6000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The L155R variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Leucine are tolerated across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Missense variants in nearby residues (D151Y, D151V) have been reported in the Human Gene Mutation Database in association with GM1-gangliosidosis (Stenson et al., 2014), supporting the functional importance of this region of the protein. We interpret L155R as a pathogenic variant.
Fulgent Genetics,Fulgent Genetics RCV000665871 SCV000894316 pathogenic GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV000809706 SCV000949875 pathogenic Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis 2019-10-07 criteria provided, single submitter clinical testing This sequence change replaces leucine with arginine at codon 155 of the GLB1 protein (p.Leu155Arg). The leucine residue is moderately conserved and there is a moderate physicochemical difference between leucine and arginine. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be homozygous / in combination with another GLB1 variant in several individuals affected with GM1-gangliosidosis, type I (PMID: 17309651, 25557439, 19472408, 20175788). ClinVar contains an entry for this variant (Variation ID: 265179). This variant has been reported to affect GLB1 protein function (PMID: 19472408). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000984003 SCV000790063 likely pathogenic Mucopolysaccharidosis, MPS-IV-B 2017-03-02 no assertion criteria provided clinical testing
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000256106 SCV000801392 likely pathogenic not provided 2017-05-31 no assertion criteria provided clinical testing
GenomeConnect - GM1 RCV001175291 SCV001338910 not provided Infantile GM1 gangliosidosis no assertion provided phenotyping only Variant interpreted as Pathogenic and reported on 09-13-2014 by Lab or GTR ID 26957. GenomeConnect-GM1 assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.